COMMITMENTS AND CONTINGENCIES (Details Narrative)													1 Months Ended					3 Months Ended	12 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Sep. 28, 2023 USD ($)	Jul. 14, 2023	May 05, 2023 shares	Dec. 05, 2022 USD ($) shares	Aug. 16, 2022 $ / shares shares	Dec. 31, 2021 USD ($)	Dec. 10, 2021 USD ($)	Jun. 10, 2021 ft²	Jan. 01, 2021 USD ($)	Sep. 24, 2020 USD ($) $ / shares	Jul. 05, 2020 USD ($) $ / shares shares	Jun. 05, 2020 USD ($) $ / shares shares	Aug. 31, 2023 shares	Mar. 31, 2023 USD ($)	Dec. 31, 2019	Mar. 31, 2018 USD ($)	Sep. 30, 2006 USD ($)	Dec. 31, 2023 USD ($) shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2017 USD ($) shares
Loss Contingencies [Line Items]
Stock options granted \| shares
Stock options aggregate \| shares																		1,660,670,920	1,664,270,920
Accrued severance payment																		$ 1,069,974	$ 1,099,974
Accrued director compensation																		267,500	252,500
Comepbsation to consultant											$ 3,000							233,625	93,845
Consideration liability																		87,440	85,640
Notes payables																		40,000	40,000
Accrued interest payable																		$ 47,440	45,640
Loss contingency damages sought value	$ 87,000						$ 100,000,000
Settlement payment description																		The Settlement Payment is payable as follows: (a) $25,000 was due and paid upon the Effective Date of the Settlement Agreement; (b) $62,000 shall be payable in three equal monthly installments as follows: (i) $20,666.67 due and paid on before October 31, 2023; (ii) $20,666.67 due on or before November 30, 2023 (iii) $20,666.67 due on or before December 31, 2023. As of December 31, 2023 and September 30, 2023, the settlement amount of $62,000 was included in accounts payable on the accompanying balance sheets.
Litigation settlement number of shares \| shares																				200,000
Litigation settlement shares, value																				$ 2,000
Employee Severance [Member]
Loss Contingencies [Line Items]
Accrued severance payment																		$ 900,000	900,000
Consulting Agreement [Member]
Loss Contingencies [Line Items]
Compensation fees									$ 2,000
Exclusive License Agreement [Member] \| George Mason University [Member]
Loss Contingencies [Line Items]
Royalty expense																	$ 50,000
Revenue percentage																	1.50%
Advance royalties																		34,792	33,533
Exclusive License Agreement [Member] \| Sublicense Royalty [Member] \| George Mason University [Member]
Loss Contingencies [Line Items]
Revenue percentage																	15.00%
License Agreement [Member] \| National Institutes of Health [Member]
Loss Contingencies [Line Items]
Royalty expense																$ 1,000
Revenue percentage																3.00%
Advance royalties																		47,928	45,409
Non refundable minimum annual royalty																$ 5,000
License Agreement [Member] \| Vanderbilt License Agreement [Member]
Loss Contingencies [Line Items]
Payments for fees														$ 18,917
Royalty expense														$ 5,556
Advance royalties																		2,328	1,909
License Agreement [Member] \| Minimum [Member] \| Vanderbilt License Agreement [Member]
Loss Contingencies [Line Items]
Revenue percentage														0.25%
License Agreement [Member] \| Maximum [Member] \| Vanderbilt License Agreement [Member]
Loss Contingencies [Line Items]
Revenue percentage														2.00%
License Agreement [Member] \| Sublicense Royalty [Member] \| National Institutes of Health [Member]
Loss Contingencies [Line Items]
Revenue percentage																10.00%
Lease Agreements [Member]
Loss Contingencies [Line Items]
Lessee operating lease description															In December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 61 months, with an option to extend, commencing in February 2020 and expiring in February 2025
Lease Amendment [Member]
Loss Contingencies [Line Items]
Rentable square feet \| ft²								4,734
Annual base rent, description								the Company must pay a total annual base rent of; (1) $115,823 for year one; (2) $119,310 for year two; (3) $122,893 for year three; (4) $126,580 for year four; (5) $130,377 for year five; (6) $135,163 for year six; (7) $139,218 for year seven; (8) $143,394 for year eight; (9) $147,696 for year nine; (10) $152,127 for year ten; (11) $156,331 for year eleven; (12) $161,391 for year twelve; (13) $166,233 for year thirteen; (14) $171,220 for year fourteen and; (15) $176,357 for year fifteen.
Dr. Michael Ruxin [Member] \| Ruxin Employment Agreement [Member]
Loss Contingencies [Line Items]
Salaries												$ 300,000
Annual decretionary bonus percentage												150.00%
Dr. Michael Ruxin [Member] \| Ruxin Employment Agreement [Member] \| 2022 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Restricted stock, shares \| shares					49,047,059							420,691,653
Stock options granted \| shares					420,691,653
Stock options aggregate \| shares					469,738,712
Stock option exercise price \| $ / shares					$ 0.0036
Dr. Michael Ruxin [Member] \| Ruxin Employment Agreement [Member] \| 2022 Equity Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Loss Contingencies [Line Items]
Restricted stock, shares \| shares												49,047,059
Jeffrey Busch [Member] \| Busch Employment Agreement [Member]
Loss Contingencies [Line Items]
Salaries												$ 60,000
Jeffrey Busch [Member] \| Busch Employment Agreement [Member] \| 2020 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Stock option exercise price \| $ / shares												$ 0.0036
Jeffrey Busch [Member] \| Busch Employment Agreement [Member] \| 2020 Equity Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Loss Contingencies [Line Items]
Restricted stock, shares \| shares					49,047,059							49,047,059
Stock options aggregate \| shares												469,738,712
Jeffrey Busch [Member] \| Busch Employment Agreement [Member] \| 2020 Equity Incentive Plan [Member] \| Share-Based Payment Arrangement, Option [Member]
Loss Contingencies [Line Items]
Stock options granted \| shares					420,691,653							420,691,653
Thomas E Chilcott, III [Member]
Loss Contingencies [Line Items]
Deferred compensation arrangements overall description						The Board also approved two new bonuses for which Mr. Chilcott was eligible: (i) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $1,000,000; and (ii) a $37,500 bonus payable upon the Company’s completion of a capital raise of at least $2,000,000 in the aggregate. On December 6, 2022, the Board approved a bonus compensation plan pursuant to which Thomas E. Chilcott, III, the Company’s Chief Financial Officer, was eligible for: (i) a $150,000 bonus payable upon the successful filing of the Company’s report on Form 10-K for the annual period ended September 30, 2022 (the “Annual Report “) on or before December 29, 2022; or (ii) a $100,000 bonus payable upon the successful filing of the Company’s Annual Report on or before January 13, 2023 (collectively, the “Bonus”). During the year ended September 30, 2023, an aggregate bonus of $150,000 was paid to Mr. Chilcott.
Thomas E Chilcott, III [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Salaries																			150,000
Annual base salary						$ 225,000
Thomas E Chilcott, III [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Salaries						$ 300,000
Thomas E Chilcott, III [Member] \| Offer Letter [Member]
Loss Contingencies [Line Items]
Salaries										$ 225,000
Stock option exercise price \| $ / shares										$ 0.0036
Deferred compensation arrangements overall description										Mr. Chilcott was entitled to participate in all medical and other benefits that the Company has established for its employees. The offer letter also provided that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock which were granted on August 16, 2022 with an exercise price of $0.0036 and an expiration date of August 15, 2032 and subject to vesting terms.
Mr Chilcott [Member]
Loss Contingencies [Line Items]
Number of non-vested options forfeited \| shares			56,727,056										37,818,040
Zaslavsky [Member]
Loss Contingencies [Line Items]
Salaries				$ 400,000
Base salary percentage				35.00%
Zaslavsky [Member] \| Share-Based Payment Arrangement, Option [Member]
Loss Contingencies [Line Items]
Sharebased compensation available for grant \| shares				150,000,000
Vesting percentage				20.00%
Consultant [Member] \| Scientific Advisory Board Service Agreement [Member]
Loss Contingencies [Line Items]
Stock option exercise price \| $ / shares											$ 0.0036
Compensation fees											$ 2,000
Payments for fees											$ 1,500
Accrued expenses																		$ 16,320	$ 15,504
Consultant [Member] \| Scientific Advisory Board Service Agreement [Member] \| 2022 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Stock options granted \| shares											88,786,943
Consultant [Member] \| Pathology Advisory Board Service Agreement [Member]
Loss Contingencies [Line Items]
Stock option exercise price \| $ / shares											$ 0.0036
Compensation fees											$ 272
Consultant [Member] \| Pathology Advisory Board Service Agreement [Member] \| 2022 Equity Incentive Plan [Member]
Loss Contingencies [Line Items]
Stock options granted \| shares											77,972,192
Dr Ruxin [Member] \| Chief Medical Officer Consulting Agreement [Member]
Loss Contingencies [Line Items]
Related party transaction, description		(a) the Company shall pay Dr, Ruxin compensation equal to $10,000 per month, (b) the Company shall amend the Dr. Ruxin’s existing option award agreement so that upon a “Separation from Service” instead of having 3 months to exercise the options, Dr. Ruxin’s options shall be exercisable until their expiration date and (c) the Company shall issue Dr. Ruxin options to purchase shares of the Company’s common stock in accordance with the Company’s newly planned Equity Incentive Plan, according to the standard amounts awarded to Chief Medical Officers, as well as taking into consideration the past 5 years of service to the company as is planned for current employees, subject to Board approval. This Agreement commenced on July 14, 2023 and will continue for one year and will be brought to the Board of Directors annually for renewal approval based on prior year performance metrics and then for subsequent one-year periods if not terminated 60 days prior to renewal

THERALINK TECHNOLOGIES, INC. 10-Q